Document Detail


Cell cycle arrest by oxaliplatin on cancer cells.
MedLine Citation:
PMID:  17391289     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oxaliplatin (L-OHP) is the only platinum compound to show activity in colorectal cancer. We evaluated the cytotoxicity of L-OHP on four human cancer cell lines and its influence on the cell cycle, when treated during long exposure (72 h) and different post-incubation times (24 or 72 h). We used a panel of cell lines: HT29 (colon cancer), MCF7 (breast cancer), Hela (uterine cervix) and A549 (lung adenocarcinoma). Inhibition concentration (IC)(50) was assessed by MTT assay. Cell cycle modifications were determined using dual parameter bromodeoxyuridine and propidium iodide. L-OHP yielded a superior cytotoxicity on HT29 and MCF7 relative to Hela and A549 after treatment, the post-incubations demonstrate that growth inhibition was irreversible for HT29 and Hela cell lines contrary to MCF7 and A549. The main effects of L-OHP are G2/M cell cycle arrest and transient S phase delay. Taken together, L-OHP treatment results on HT29, MCF7 and Hela, are in favor of lengthening the infusion duration to patients during further clinical trials.
Authors:
Sara William-Faltaos; Dany Rouillard; Philippe Lechat; Gérard Bastian
Related Documents :
18395779 - Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative ...
19073149 - Regression of prostate cancer xenografts by rlip76 depletion.
6148619 - Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro.
18486529 - Rnai-mediated downregulation of urokinase plasminogen activator receptor inhibits proli...
19963049 - Effective antiproliferative effect of meloxicam on prostate cancer cells: development o...
9365549 - Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer...
24155219 - Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer ce...
1925139 - Local therapy for breast cancer: treatment choices and decision making.
18395779 - Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  21     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-29     Completed Date:  2007-06-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  165-72     Citation Subset:  IM    
Affiliation:
Pharmacology Department, Faculty of Medicine, Pitie-Salpetriere Hospital, 91 Boulevard de l'Hôpital, Door: 417-418, 75634 Paris Cedex 13, France. sara@chups.jussieu.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage,  pharmacology*
Bromodeoxyuridine
Cell Cycle / drug effects*
Cell Line, Tumor
Cell Survival / drug effects*
Female
Flow Cytometry
Humans
Infusions, Intravenous
Organoplatinum Compounds / administration & dosage,  pharmacology*
Propidium
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 36015-30-2/Propidium; 59-14-3/Bromodeoxyuridine; 63121-00-6/oxaliplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant s...
Next Document:  A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after car...